Our Partners
Partnerships
Working Together to Advance Cancer Immunotherapies Development
Industry Partners
Industry collaboration is central to accelerating innovation. We work with biotechnology and pharmaceutical companies to bring discoveries closer to market and to patients.
- Non-dilutive funding to reduce early-stage risk.
- Access to core facilities, infrastructure, and scientific expertise.
- Support in the translational research phase, bridging discovery to the clinic.
By de-risking the development process, we encourage additional investment, speed and support entry into clinical trials, and improve the likelihood of success.
- Co-develop technologies to advance into the next phase.
- Fund rational combinations of biotherapeutics.
- Invest in internationally peer-reviewed projects.
- Generate better data to improve patient safety and therapy outcomes.
Academic & Institutional Partners
Our academic and institutional partners are the backbone of BioCanRx’s translational research model.
They house the researchers, clinicians, facilities, and patients who make progress possible. With their investments, expertise and facility support, projects are able to move efficiently toward clinical trials.
Some institutions also receive operational funding from BioCanRx to serve as Core Facilities. These hubs of manufacturing, commercialization, and immune-monitoring expertise ensure researchers from the public and private sectors have timely access to the specialized resources needed to advance their projects.
Patient Groups & Not-for-Profits
- Embedding the patient voice into clinical trial design.
- Ensuring investments focus on innovative therapies with real-world impact.
- Aligning stakeholders with a shared mission to deliver curative treatments.
By combining expertise, advocacy, and resources, these partnerships accelerate access to cancer immunotherapies and deliver better outcomes for patients across Canada.